AIM:To assess whether gemcitabine-based combination therapy improves the prognosis of unresectable pancreatic cancer compared with gemcitabine treatment alone.METHODS:A quantitative up-to-date meta-analysis was undert...AIM:To assess whether gemcitabine-based combination therapy improves the prognosis of unresectable pancreatic cancer compared with gemcitabine treatment alone.METHODS:A quantitative up-to-date meta-analysis was undertaken to investigate the efficacy of gemcitabine-based combination treatment compared with gemcitabine monotherapy in locally advanced or metastatic pancreatic cancer.Inclusion was limited to highquality randomized clinical trials.RESULTS:Twenty-six studies were included in the present analysis,with a total of 8808 patients recruited.The studies were divided into four subgroups based on the different kinds of cytotoxic agents,including platinum,fluoropyrimidine,camptothecin and targeted agents.Patients treated with gemcitabine monotherapy had significantly lower objective response rate [risk ratio(RR),0.72;95% confidence interval(CI):0.63-0.83;P < 0.001],and lower 1-year overall survival(RR,0.90;95%CI:0.82-0.99;P = 0.04).Gemcitabine monotherapy caused fewer complications,including fewer grade 3-4 toxicities:including vomiting(RR,0.75;95%CI:0.62-0.89;P = 0.001),diarrhea(RR,0.66;95%CI:0.49-0.89;P = 0.006),neutropenia(RR,0.88;95%CI:0.72-1.06;P = 0.18),anemia(RR,0.96;95%CI:0.82-1.12;P = 0.60),and thrombocytopenia(RR,0.76;95%CI:0.60-0.97;P = 0.03) compared with gemcitabine combination therapies.CONCLUSION:Gemcitabine combination therapy provides a modest improvement of survival,but is associated with more toxicity compared with gemcitabine monotherapy.展开更多
目的研究卡铂与磷脂酰肌醇3-激酶(phosphoinositide 3-kinase,PI3K)抑制剂PF-04691502(PF)联合抗人三阴性乳腺癌(triple-negative breast cancer,TNBC)细胞的作用。方法通过细胞增殖实验、克隆形成实验、细胞划痕愈合实验以及流式细胞...目的研究卡铂与磷脂酰肌醇3-激酶(phosphoinositide 3-kinase,PI3K)抑制剂PF-04691502(PF)联合抗人三阴性乳腺癌(triple-negative breast cancer,TNBC)细胞的作用。方法通过细胞增殖实验、克隆形成实验、细胞划痕愈合实验以及流式细胞技术来分析卡铂和PF对TNBC细胞(HCC1937和MDA-MB 231)的抑制作用,并通过ELISA实验来检测PF对肿瘤发生过程中的关键蛋白Akt磷酸化的抑制作用。结果细胞增殖实验发现卡铂与PF对TNBC细胞均有协同抑制作用(CI<1);还能有效地抑制TNBC细胞克隆的形成和迁移(P<0.01)。ELISA实验发现PF对TNBC细胞Akt的磷酸化也具有一定的抑制作用,并且具有浓度依赖性。流式细胞结果显示PF对TNBC细胞G1期有阻滞作用,而卡铂为周期非特异性药物。结论卡铂联合PF具有协同抗TNBC细胞的作用;并提示化疗药物联合PI3K抑制剂也许能够提高TNBC的治疗效果,并减少化疗药物的给药剂量、降低毒副作用。展开更多
文摘AIM:To assess whether gemcitabine-based combination therapy improves the prognosis of unresectable pancreatic cancer compared with gemcitabine treatment alone.METHODS:A quantitative up-to-date meta-analysis was undertaken to investigate the efficacy of gemcitabine-based combination treatment compared with gemcitabine monotherapy in locally advanced or metastatic pancreatic cancer.Inclusion was limited to highquality randomized clinical trials.RESULTS:Twenty-six studies were included in the present analysis,with a total of 8808 patients recruited.The studies were divided into four subgroups based on the different kinds of cytotoxic agents,including platinum,fluoropyrimidine,camptothecin and targeted agents.Patients treated with gemcitabine monotherapy had significantly lower objective response rate [risk ratio(RR),0.72;95% confidence interval(CI):0.63-0.83;P < 0.001],and lower 1-year overall survival(RR,0.90;95%CI:0.82-0.99;P = 0.04).Gemcitabine monotherapy caused fewer complications,including fewer grade 3-4 toxicities:including vomiting(RR,0.75;95%CI:0.62-0.89;P = 0.001),diarrhea(RR,0.66;95%CI:0.49-0.89;P = 0.006),neutropenia(RR,0.88;95%CI:0.72-1.06;P = 0.18),anemia(RR,0.96;95%CI:0.82-1.12;P = 0.60),and thrombocytopenia(RR,0.76;95%CI:0.60-0.97;P = 0.03) compared with gemcitabine combination therapies.CONCLUSION:Gemcitabine combination therapy provides a modest improvement of survival,but is associated with more toxicity compared with gemcitabine monotherapy.
文摘目的研究卡铂与磷脂酰肌醇3-激酶(phosphoinositide 3-kinase,PI3K)抑制剂PF-04691502(PF)联合抗人三阴性乳腺癌(triple-negative breast cancer,TNBC)细胞的作用。方法通过细胞增殖实验、克隆形成实验、细胞划痕愈合实验以及流式细胞技术来分析卡铂和PF对TNBC细胞(HCC1937和MDA-MB 231)的抑制作用,并通过ELISA实验来检测PF对肿瘤发生过程中的关键蛋白Akt磷酸化的抑制作用。结果细胞增殖实验发现卡铂与PF对TNBC细胞均有协同抑制作用(CI<1);还能有效地抑制TNBC细胞克隆的形成和迁移(P<0.01)。ELISA实验发现PF对TNBC细胞Akt的磷酸化也具有一定的抑制作用,并且具有浓度依赖性。流式细胞结果显示PF对TNBC细胞G1期有阻滞作用,而卡铂为周期非特异性药物。结论卡铂联合PF具有协同抗TNBC细胞的作用;并提示化疗药物联合PI3K抑制剂也许能够提高TNBC的治疗效果,并减少化疗药物的给药剂量、降低毒副作用。